X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (142058) 142058
Newsletter (27496) 27496
Book Review (21030) 21030
Newspaper Article (17490) 17490
Publication (9753) 9753
Conference Proceeding (1017) 1017
Trade Publication Article (997) 997
Book Chapter (898) 898
Magazine Article (825) 825
Web Resource (366) 366
Dissertation (347) 347
Transcript (227) 227
Book / eBook (175) 175
Government Document (48) 48
Report (42) 42
Reference (36) 36
Paper (21) 21
Data Set (15) 15
Journal / eJournal (10) 10
Streaming Video (4) 4
Poster (3) 3
Presentation (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (101948) 101948
humans (95909) 95909
male (53888) 53888
hepatitis (53761) 53761
female (52095) 52095
adult (41057) 41057
middle aged (40901) 40901
hepatitis c virus (36700) 36700
hepatitis c (36404) 36404
gastroenterology & hepatology (32349) 32349
health aspects (25623) 25623
research (22927) 22927
hepatitis b (22589) 22589
interferon (21755) 21755
aged (21214) 21214
liver (21066) 21066
infection (20861) 20861
medical research (16819) 16819
antiviral agents - therapeutic use (15639) 15639
risk factors (15601) 15601
hepatitis b virus (14908) 14908
infections (14870) 14870
liver diseases (14836) 14836
care and treatment (14726) 14726
medicine, experimental (13984) 13984
virology (13801) 13801
infectious diseases (13665) 13665
analysis (13290) 13290
animals (13193) 13193
immunology (11885) 11885
liver cirrhosis (11743) 11743
adolescent (11732) 11732
hepatitis c, chronic - drug therapy (11686) 11686
virus diseases (11082) 11082
cirrhosis (11078) 11078
prevalence (11027) 11027
genotype (10845) 10845
treatment outcome (10816) 10816
abridged index medicus (10419) 10419
hepacivirus - genetics (10368) 10368
disease (10139) 10139
liver cancer (10119) 10119
viruses (10023) 10023
antiviral agents (9939) 9939
therapy (9385) 9385
virus-infection (9273) 9273
hepatocellular-carcinoma (8898) 8898
hepatocellular carcinoma (8747) 8747
biological response modifiers (8662) 8662
drug therapy (8575) 8575
patients (8566) 8566
genetic aspects (8555) 8555
liver - pathology (8282) 8282
cancer (8203) 8203
ribavirin (8137) 8137
interferon-alpha - therapeutic use (8032) 8032
fibrosis (7996) 7996
medicine, general & internal (7697) 7697
retrospective studies (7620) 7620
young adult (7594) 7594
diagnosis (7510) 7510
gastroenterology and hepatology (7369) 7369
epidemiology (7346) 7346
communicable diseases (7194) 7194
drug therapy, combination (7124) 7124
hepatitis c, chronic - complications (7084) 7084
hiv (7002) 7002
chronic disease (6995) 6995
chronic hepatitis-c (6976) 6976
transplantation (6951) 6951
oncology (6834) 6834
hepatitis b virus - genetics (6811) 6811
medicine (6689) 6689
biopsy (6647) 6647
hepatology (6596) 6596
pharmacology & pharmacy (6534) 6534
child (6505) 6505
prognosis (6500) 6500
hcv (6415) 6415
mortality (6293) 6293
pharmaceutical industry (6262) 6262
digestive system diseases (6224) 6224
studies (6037) 6037
mice (5991) 5991
proteins (5931) 5931
surgery (5814) 5814
hepatitis c - complications (5784) 5784
human immunodeficiency virus--hiv (5777) 5777
development and progression (5723) 5723
rna (5684) 5684
expression (5642) 5642
research article (5596) 5596
hepatitis-c virus (5566) 5566
microbiology (5504) 5504
ribavirin - therapeutic use (5503) 5503
medicine & public health (5480) 5480
viral load (5470) 5470
antigens (5459) 5459
time factors (5407) 5407
risk (5403) 5403
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (90) 90
Online Resources - Online (40) 40
Collection Dvlpm't (Acquisitions) - Vendor file (9) 9
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (3) 3
Scarborough Hospital - Online (2) 2
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (2) 2
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Mt Sinai Hospital - Pathology (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
UTL at Downsview - May be requested (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (180386) 180386
French (2122) 2122
Spanish (1571) 1571
German (1349) 1349
Japanese (1090) 1090
Chinese (906) 906
Korean (872) 872
Russian (710) 710
Italian (400) 400
Portuguese (372) 372
Polish (343) 343
Turkish (211) 211
Hungarian (164) 164
Romanian (114) 114
Czech (101) 101
Croatian (89) 89
Serbian (41) 41
Dutch (38) 38
Danish (32) 32
Swedish (27) 27
Persian (26) 26
Norwegian (19) 19
Slovak (18) 18
Hebrew (13) 13
Ukrainian (9) 9
Bosnian (7) 7
Slovenian (6) 6
Urdu (6) 6
Finnish (5) 5
Bulgarian (4) 4
Icelandic (3) 3
Lithuanian (3) 3
Belarusian (2) 2
Catalan (2) 2
Albanian (1) 1
Azerbaijani (1) 1
Hindi (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2429 - 2438
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 10003, pp. 1537 - 1545
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2405 - 2416
In patients with HCV infection and no previous treatment, the addition of telaprevir to peginterferon–ribavirin resulted in higher response rates than those... 
UNITED-STATES | TRIAL | GENETIC-VARIATION | CLEARANCE | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | GENOTYPE-1 PATIENTS | PEGINTERFERON ALPHA-2B | AMERICAN PATIENTS | CHRONIC HCV INFECTION | ALPHA-2B PLUS RIBAVIRIN | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Oligopeptides - therapeutic use | Serine Proteinase Inhibitors - therapeutic use | Young Adult | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Logistic Models | Hepatitis C, Chronic - drug therapy | Sequence Analysis, DNA | Antiviral Agents - adverse effects | Aged | Interferon-alpha - adverse effects | Peginterferon alfa-2b | Patient outcomes | Genetic aspects | Hepatitis C | Drug therapy | Comparative analysis | Health aspects | Fees & charges | Antiretroviral drugs | Liver diseases | Clinical trials | Chronic infection | Employees | Infections | Proteinase inhibitors | Genomes | Ribonucleic acid--RNA | Patients | Ribavirin | Liver cancer | Genotype & phenotype | Hepatitis | Skin | Interferon | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
10/2019, ISBN 9783030037567, 220
eBook
Annals of Internal Medicine, ISSN 0003-4819, 07/2015, Volume 163, Issue 1, pp. 1 - 13
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 07/2013, Volume 159, Issue 2, pp. 86 - 96
Background: Telaprevir (TVR) plus peginterferon-alpha 2a (PEG-IFN-alpha 2a) and ribavirin substantially increases treatment efficacy for genotype 1 chronic... 
Vertex pharmaceuticals and janssen pharmaceuticals | MEDICINE, GENERAL & INTERNAL | COINFECTED PATIENTS | MANAGEMENT | RECOMMENDATIONS | PREDICTORS | BOCEPREVIR | HCV | UPDATE | VIROLOGICAL RESPONSE | ASSOCIATION | INTERFERON PLUS RIBAVIRIN | HIV-1 | Recombinant Proteins - therapeutic use | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - pharmacokinetics | Recombinant Proteins - adverse effects | Oligopeptides - adverse effects | Polyethylene Glycols - therapeutic use | Oligopeptides - therapeutic use | Ribavirin - pharmacokinetics | Interferon-alpha - pharmacokinetics | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Double-Blind Method | Antiviral Agents - therapeutic use | Oligopeptides - pharmacokinetics | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Polyethylene Glycols - pharmacokinetics | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Ribavirin - adverse effects | Antiviral Agents - adverse effects | HIV Infections - complications | Interferon-alpha - adverse effects | Antiviral agents | Patient outcomes | Dosage and administration | Drug therapy, Combination | Research | Hepatitis C | Drug therapy | HIV infection | Drugs | Clinical trials | Hepatitis | Side effects | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 2012, Volume 156, Issue 4, pp. 279 - 290
Journal Article
Alimentary Pharmacology & Therapeutics, ISSN 0269-2813, 05/2018, Volume 47, Issue 9, pp. 1238 - 1252
BackgroundChronic hepatitis C is considered a systemic disease because of extra-hepatic manifestations. Neuroimaging has been employed in hepatitis C... 
INTERFERON-ALPHA | MAGNETIC-RESONANCE-SPECTROSCOPY | VIRUS-INFECTION | MICROGLIAL ACTIVATION | CORTICAL THICKNESS | IN-VIVO | PSYCHIATRIC-DISORDERS | COGNITIVE IMPAIRMENT | PHARMACOLOGY & PHARMACY | MAJOR DEPRESSION | HCV-POSITIVE PATIENTS | GASTROENTEROLOGY & HEPATOLOGY | Neuroimaging - methods | Brain - diagnostic imaging | Hepatitis C, Chronic - pathology | Liver Cirrhosis - diagnosis | Magnetic Resonance Spectroscopy | Central Nervous System Viral Diseases - diagnosis | Humans | Brain - virology | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - diagnosis | Central Nervous System Viral Diseases - etiology | Diffusion Tensor Imaging | Brain - metabolism | Magnetic Resonance Imaging | Liver Cirrhosis - virology | Liver Cirrhosis - pathology | Adult | Female | Liver | Nuclear magnetic resonance spectroscopy | Internet/Web search services | Diagnostic imaging | Glutamate | Database searching | Creatine | Online searching | Tomography | Hepatitis C virus | Hepatitis C | Health aspects | Liver cirrhosis | Glutamine | Neuroimaging | Brain | Basal ganglia | Image processing | Emission analysis | Central nervous system | Chronic infection | Spectroscopic analysis | Viruses | Systematic review | Cognition | Mental depression | Magnetic resonance spectroscopy | Confidence intervals | Hepatitis | Alterations | Computed tomography | Encephalopathy | Spectrum analysis | Photon emission | Spectroscopy | Liver diseases | Medical imaging | Abnormalities | Cortex | Positron emission | Fatigue | Patients | Ganglia | Emissions | Neurology | Cirrhosis | Magnetic resonance imaging | Perfusion | Neural networks | Choline | Emissions control | Resonance | Interferon | Positron emission tomography | Index Medicus
Journal Article